Autolus Therapeutics (AUTL) Receives a Buy from Mizuho Securities

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTLResearch Report), with a price target of $18.00. The company’s shares opened today at $2.81.

According to TipRanks, Goldstein is a 2-star analyst with an average return of 0.1% and a 34.46% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Merck & Company, and Adaptimmune Therapeutics.

Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.25.

See the top stocks recommended by analysts >>

Based on Autolus Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $42.06 million. In comparison, last year the company earned a revenue of $1.51 million and had a GAAP net loss of $33.17 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Read More on AUTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More